Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-Dex
- Development stage
- Preclinical
- Lead developer
- Dextech Solutions
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PSMA-Dex is a preclinical-stage therapeutic candidate developed by DexTech Medical AB for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is built upon the company's proprietary GuaDex platform, which utilizes a charge-modified, polysulfated dextran backbone with inherent anti-tumor properties. PSMA-Dex specifically incorporates a PSMA-binding tripeptide to target prostate-specific membrane antigen (PSMA), which is highly overexpressed in advanced prostate cancer cells. This conjugate is designed to deliver either radioligand therapy or cytostatic payloads directly to the tumor site, combining the targeting specificity of PSMA ligands with the cytotoxic effects of the GuaDex platform and its attached cargo.
- Other names
- PSMA-tripeptide polysulfated dextran conjugate
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-Dex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-Dex.